Ice Miller client Schrödinger, Inc. (NASDAQ: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s portfolio for further development. The companies also announced an expanded three-year software agreement that substantially increases Novartis's access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform. 

The full press release can be found here.

As part of the agreement, Schrödinger will receive $150 million upfront payment, with eligibility to receive up to approximately $2.3 billion in milestone payments plus royalties on each product commercialized by Novartis.

Ice Miller’s rapidly growing Life Sciences team has been counseling Schrödinger since 2022 and continues to support the company in their growth utilizing its computational predictive modeling technology for drug discovery. The Ice Miller deal team was led by Business Group Partner TaeSoo Sean Kim and included Mai Zymaris and Simone Park, with additional deal support from Nancy Kartos and Xuan Feng. Specialist support was provided by Anthony Aaron (Regulatory/Antitrust), Grace Dahm (Regulatory/Antitrust), Daniel Corsaro (Tax), Pierce Han (SEC/Capital Markets), Fabian Koenigbauer (IP), and Ethan Rii (Healthcare).